Trofopar treatment of chronic liver diseases.
The clinical study on the Romanian product Trofopar was performed on 71 patients affected by chronic liver diseases; of them 30 patients suffered from cirrhosis decompensated at the parenchymal and vascular level. The clinical results corroborated with laboratory tests substantiate the efficacy of Trofopar, which improves liver blood circulation, increases the capacity of hepatocyte regeneration, detoxification and metabolization.
Loghinov
A S
AS
Central Unional Institute for Gastroenterology, Moscow, USSR.
Suhareva
G V
GV
Bendikov
E A
EA
Blok
I E
IE
Astasenkova
C J
CJ
Nicolaeva
A P
AP
D000293:Adolescent; D000328:Adult; D000368:Aged; D000983:Antipyrine; D002908:Chronic Disease; D005260:Female; D006521:Hepatitis, Chronic / Q000097:blood / Q000188:drug therapy; D006801:Humans; D007930:Leucine / Q000097:blood / Q000187:drug effects; D008103:Liver Cirrhosis / Q000097:blood / Q000188:drug therapy; D008107:Liver Diseases / Q000097:blood / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D010455:Peptides / Q000627:therapeutic use*; D012074:Remission Induction
D010455:Peptides; C071168:trofopar; D007930:Leucine; D000983:Antipyrine